Abstract
Production of 68Ga-radiopharmaceuticals for Positron Emission Tomography coupled with Computed Tomography (PET/CT) is increasing. These developments are today consolidated by the availability in France of a somatostatin receptor agonist (DOTATOC, Somakit®), under marketed authorization, and two Prostate Specific Membrane Antigen (PSMA) inhibitors (PSMA-11 and PSMA-617) under nominative temporary authorization of use. The unquestionable success of these radiopharmaceuticals and their uses within diagnostic strategies represent clinical trials carried out using 68Ga-DOTATOC and 68Ga-PSMA-11 mainly. Today, new indications and new 68Ga-radiopharmaceuticals arise to further promote PET/CT molecular imaging. In this article, we would share our experience to establish such clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
